Whether Epclusa is a free national drug and policy explanation

Epclusa (Epclusa/Epclusa) is an oral, fully oral anti-hepatitis C virus (HCV) drug, consisting of sofosbuvir ( It is composed of pan>Sofosbuvir) and Velpatasvir (Velpatasvir), which has the advantage of pan-genotypic treatment and can be used to treat hepatitis C of most genotypes. Jisandai has been launched in China and has entered the medical insurance catalog, providing more accessibility and economic burden reduction opportunities for eligible patients.

Although Jisandai is currently included in medical insurance, is not included in the national free drug list. In other words, when patients use Jisanda to treat hepatitis C in China, they can enjoy the medical insurance reimbursement policy, and the actual expenditure is lower, but it is not a completely free drug. The state has gradually increased its support for the prevention and control of hepatitis C, but at this stage, it is more about reducing the cost of medication through medical insurance negotiations, price negotiations, etc., rather than providing it completely free of charge.

In the domestic market, the price of Jisandai is about more than 3,000 yuan (taking one box as an example). Patients can purchase it at regular hospital pharmacies and receive partial reimbursement through medical insurance. The actual cost may be further reduced. Medical insurance reimbursement ratios vary in different regions, and you need to consult the local hospital or medical insurance department for specific prices. In comparison, generic versions of drugs in India and Bangladesh are cheaper, usually around a few hundred yuan per course of treatment, and their ingredients are basically the same as domestic original drugs. However, when purchasing in the domestic market, you need to carefully choose the channel to ensure that the source is regular and safe.

Overall, Jisandai is not a free drug in the country, but with its inclusion in the medical insurance catalog, the financial burden on patients has been greatly reduced. For patients, priority should be given to obtaining prescriptions from regular hospitals, and treatment should be combined with medical insurance reimbursement policies; if considering overseas generic drugs, they should fully understand the legality of the channels and drug quality assurance. In the future, as the country advances its hepatitis C prevention and control policies, patients are expected to enjoy more policy support, but at this stage, they still need to rely on medical insurance reimbursement rather than completely free medication.

Reference materials:https://www.drugs.com/